{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:23:24Z","timestamp":1792531404675,"version":"4.5.0"},"reference-count":101,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,30]]},"abstract":"<jats:p>Malaria continues to be a global health threat, affecting approximately 219 million people in 2018 alone. The recurrent development of resistance to existing antimalarials means that the design of new drug candidates must be carefully considered. Understanding of drug target mechanism can dramatically accelerate early-stage target-based development of novel antimalarials and allows for structural modifications even during late-stage preclinical development. Here, we have provided an overview of three promising antimalarial molecular targets, PfDHFR, PfDHODH and PfA-M1, and their associated inhibitors which demonstrate how mechanism can inform drug design and be effectively utilised to generate compounds with potent inhibitory activity.<\/jats:p>","DOI":"10.1042\/bst20200224","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T10:48:31Z","timestamp":1598957311000},"page":"2067-2078","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Driving antimalarial design through understanding of target mechanism"],"prefix":"10.1042","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-2394","authenticated-orcid":false,"given":"Petar P. S.","family":"Calic","sequence":"first","affiliation":[{"name":"Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-5370","authenticated-orcid":false,"given":"Mahta","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-895X","authenticated-orcid":false,"given":"Peter J.","family":"Scammells","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-1106","authenticated-orcid":false,"given":"Sheena","family":"McGowan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2020103011412900000_BST-2020-0224CC1","volume-title":"World Malaria Report 2019","author":"WHO","year":"2019"},{"key":"2020103011412900000_BST-2020-0224CC2","volume-title":"Global Technical Strategy for Malaria 2016\u20132030","author":"WHO","year":"2015"},{"key":"2020103011412900000_BST-2020-0224CC3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrmicro2331","article-title":"Artemisinin resistance: current status and scenarios for containment","volume":"8","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"2020103011412900000_BST-2020-0224CC4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/QCO.0b013e32834cd3ed","article-title":"Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum","volume":"24","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2020103011412900000_BST-2020-0224CC5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2174\/156802611795429176","article-title":"Finding new hits in neglected disease projects: target or phenotypic based screening?","volume":"11","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"2020103011412900000_BST-2020-0224CC7","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1021\/jm4004279","article-title":"Approaches to protozoan drug discovery: phenotypic screening","volume":"56","year":"2013","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC8","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1016\/S0021-9258(17)43186-3","article-title":"The functional human dihydrofolate reductase gene","volume":"259","year":"1984","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1096\/fasebj.4.6.2180768","article-title":"Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa","volume":"4","year":"1990","journal-title":"FASEB J."},{"key":"2020103011412900000_BST-2020-0224CC10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nsb921","article-title":"Insights into antifolate resistance from malarial DHFR-TS structures","volume":"10","year":"2003","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2020103011412900000_BST-2020-0224CC11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/jac\/dkl104","article-title":"The past, present and future of antifolates in the treatment of Plasmodium falciparum infection","volume":"57","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"2020103011412900000_BST-2020-0224CC12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jac\/36.5.857","article-title":"Conflicts of interest: the genesis of synthetic antimalarial agents in peace and War","volume":"36","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"2020103011412900000_BST-2020-0224CC13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1542\/pir.21-11-368","article-title":"Review of the sulfonamides and trimethoprim","volume":"21","year":"2000","journal-title":"Pediatr. Rev."},{"key":"2020103011412900000_BST-2020-0224CC14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"2020103011412900000_BST-2020-0224CC15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminopterin)","volume":"238","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"2020103011412900000_BST-2020-0224CC16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/pr.57.1.4","article-title":"Mechanisms of resistance of malaria parasites to antifolates","volume":"57","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"2020103011412900000_BST-2020-0224CC17","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1021\/acs.jmedchem.9b00761","article-title":"The development process for discovery and clinical advancement of modern antimalarials","volume":"62","year":"2019","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC18","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1128\/AAC.48.6.2116-2123.2004","article-title":"Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum","volume":"48","year":"2004","journal-title":"Antimicrob. Agents. Chemother."},{"key":"2020103011412900000_BST-2020-0224CC19","doi-asserted-by":"publisher","first-page":"9109","DOI":"10.1073\/pnas.85.23.9109","article-title":"Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum","volume":"85","year":"1988","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020103011412900000_BST-2020-0224CC20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1383-5769(98)80253-5","article-title":"Molecular basis in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum","volume":"42","year":"1998","journal-title":"Parasitol. Int."},{"key":"2020103011412900000_BST-2020-0224CC21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/bcp.14219","article-title":"First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection","volume":"86","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2020103011412900000_BST-2020-0224CC22","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1073\/pnas.85.23.9114","article-title":"Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria","volume":"85","year":"1988","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020103011412900000_BST-2020-0224CC23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0166-6851(01)00207-9","article-title":"Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210","volume":"113","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"2020103011412900000_BST-2020-0224CC24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0166-6851(02)00035-X","article-title":"Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding","volume":"121","year":"2002","journal-title":"Mol. Biochem. Parasitol."},{"key":"2020103011412900000_BST-2020-0224CC25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1017\/S003118200400664X","article-title":"Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors","volume":"130","year":"2005","journal-title":"Parasitology"},{"key":"2020103011412900000_BST-2020-0224CC26","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1021\/jm010131q","article-title":"Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R + S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum","volume":"45","year":"2002","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0035-9203(96)90326-0","article-title":"Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model","volume":"90","year":"1996","journal-title":"Trans. Roy. Soc. Trop. Med. Hyg."},{"key":"2020103011412900000_BST-2020-0224CC28","doi-asserted-by":"publisher","first-page":"16823","DOI":"10.1073\/pnas.1204556109","article-title":"Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target","volume":"109","year":"2012","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020103011412900000_BST-2020-0224CC29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115158","article-title":"6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum","volume":"27","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC30","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.bmc.2017.05.054","article-title":"1,2,4-triazole and 1,3,4-oxadiazole analogues: synthesis, MO studies, in silico molecular docking studies, antimalarial as dhfr inhibitor and antimicrobial activities","volume":"25","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC31","first-page":"2654","article-title":"4-aminoquinoline-1,3,5-triazine: design, synthesis, in vitro antimalarial activity and docking studies","volume":"37","year":"2013","journal-title":"New J. Chem."},{"key":"2020103011412900000_BST-2020-0224CC32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/07391102.2014.979231","article-title":"Origins of the specificity of inhibitor P218 toward wild-type and mutant Pfdhfr: a molecular dynamics analysis","volume":"33","year":"2015","journal-title":"J. Biomol. Struct. Dyn."},{"key":"2020103011412900000_BST-2020-0224CC33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0304-4165(94)00158-T","article-title":"Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite","volume":"1243","year":"1995","journal-title":"Biochim. Biophys. Acta. Gen. Subj."},{"key":"2020103011412900000_BST-2020-0224CC34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/138945007779315524","article-title":"Targeting purine and pyrimidine metabolism in human apicomplexan parasites","volume":"8","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"2020103011412900000_BST-2020-0224CC35","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature01097","article-title":"Genome sequence of the human malaria parasite Plasmodium falciparum","volume":"419","year":"2002","journal-title":"Nature"},{"key":"2020103011412900000_BST-2020-0224CC36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0166-6851(01)00429-7","article-title":"Rna interference (Rnai) inhibits growth of Plasmodium falciparum","volume":"119","year":"2002","journal-title":"Mol. Biochem. Parasitol."},{"key":"2020103011412900000_BST-2020-0224CC37","doi-asserted-by":"publisher","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A long-Duration dihydroorotate dehydrogenase inhibitor (Dsm265) for prevention and treatment of malaria","volume":"7","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2020103011412900000_BST-2020-0224CC38","doi-asserted-by":"publisher","first-page":"14926","DOI":"10.1021\/bi060919g","article-title":"Mechanism of flavin reduction in class 2 dihydroorotate dehydrogenases","volume":"45","year":"2006","journal-title":"Biochemistry"},{"key":"2020103011412900000_BST-2020-0224CC39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.4155\/fmc-2017-0250","article-title":"Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria","volume":"10","year":"2018","journal-title":"Future Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/187152610791163336","article-title":"Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy","volume":"10","year":"2010","journal-title":"Infect. Disord. Drug. Targets"},{"key":"2020103011412900000_BST-2020-0224CC41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1107\/s0907444905042642","article-title":"Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor","volume":"62","year":"2006","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"2020103011412900000_BST-2020-0224CC42","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.1021\/bi8003318","article-title":"The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites","volume":"47","year":"2008","journal-title":"Biochemistry"},{"key":"2020103011412900000_BST-2020-0224CC43","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1021\/bi702218c","article-title":"Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase","volume":"47","year":"2008","journal-title":"Biochemistry"},{"key":"2020103011412900000_BST-2020-0224CC44","doi-asserted-by":"publisher","first-page":"26999","DOI":"10.1074\/jbc.m109.028589","article-title":"Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds","volume":"284","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC45","doi-asserted-by":"publisher","first-page":"41827","DOI":"10.1074\/jbc.M206854200","article-title":"Malarial dihydroorotate dehydrogenase: substrate and inhibitor specificity","volume":"277","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC46","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.bmc.2005.01.017","article-title":"Synthesis of Brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase","volume":"13","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC47","doi-asserted-by":"publisher","first-page":"21847","DOI":"10.1074\/jbc.m501100200","article-title":"High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"280","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC48","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1021\/jm800963t","article-title":"Structure-Based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases","volume":"52","year":"2009","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0969-2126(00)00077-0","article-title":"Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents","volume":"8","year":"2000","journal-title":"Structure"},{"key":"2020103011412900000_BST-2020-0224CC50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bmcl.2005.09.045","article-title":"The first De novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"16","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2020103011412900000_BST-2020-0224CC51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1021\/jm060687j","article-title":"Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase","volume":"50","year":"2007","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC52","doi-asserted-by":"publisher","first-page":"35078","DOI":"10.1074\/jbc.M804990200","article-title":"Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"283","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bmcl.2015.12.043","article-title":"Comparative study between 3d-Qsar and docking-Based pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors","volume":"26","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2020103011412900000_BST-2020-0224CC54","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.bmcl.2009.11.079","article-title":"A study of the effects of substituents on the selectivity of the binding of N-arylaminomethylene malonate inhibitors to Dhodh","volume":"20","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2020103011412900000_BST-2020-0224CC55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acs.jcim.5b00680","article-title":"Identification of new human malaria parasite Plasmodium falciparum dihydroorotate dehydrogenase inhibitors by pharmacophore and structure-based virtual screening","volume":"56","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"2020103011412900000_BST-2020-0224CC56","doi-asserted-by":"publisher","first-page":"33054","DOI":"10.1074\/jbc.M110.162081","article-title":"Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-Malarial activity in the mouse model","volume":"285","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC57","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1021\/ml200143c","article-title":"Optimization of potent inhibitors of P. falciparum dihydroorotate dehydrogenase for the treatment of malaria","volume":"2","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"2020103011412900000_BST-2020-0224CC58","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1073\/pnas.1320886110","article-title":"Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance","volume":"111","year":"2014","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020103011412900000_BST-2020-0224CC59","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1021\/acs.jmedchem.0c00311","article-title":"Lead optimization of a pyrrole-Based dihydroorotate dehydrogenase inhibitor series for the treatment of malaria","volume":"63","year":"2020","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC60","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1021\/jm801343r","article-title":"Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice","volume":"52","year":"2009","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC61","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1021\/jm200265b","article-title":"Lead optimization of aryl and aralkyl amine-Based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice","volume":"54","year":"2011","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC62","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1021\/acsinfecdis.6b00144","article-title":"A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-Like properties for treatment and prevention of malaria","volume":"2","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"2020103011412900000_BST-2020-0224CC63","doi-asserted-by":"publisher","first-page":"106580","DOI":"10.1016\/j.vascn.2019.106580","article-title":"Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats","volume":"99","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2020103011412900000_BST-2020-0224CC64","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1021\/jm200592f","article-title":"Structure-Guided lead optimization of triazolopyrimidine-Ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential","volume":"54","year":"2011","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC65","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose Dsm265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or plasmodium vivax malaria infection: a proof-of-Concept, open-label, phase 2a study","volume":"18","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"2020103011412900000_BST-2020-0224CC66","doi-asserted-by":"publisher","first-page":"e01371","DOI":"10.1128\/AAC.01371-19","article-title":"A single-dose combination study with the experimental antimalarials artefenomel and Dsm265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers","volume":"64","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"2020103011412900000_BST-2020-0224CC67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/infdis\/jix613","article-title":"A randomized trial evaluating the prophylactic activity of Dsm265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation","volume":"217","year":"2017","journal-title":"J. Infect. Dis."},{"key":"2020103011412900000_BST-2020-0224CC68","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"Dsm265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection","volume":"17","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"2020103011412900000_BST-2020-0224CC69","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1021\/acsomega.8b01573","article-title":"Isoxazolopyrimidine-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity","volume":"3","year":"2018","journal-title":"ACS Omega"},{"key":"2020103011412900000_BST-2020-0224CC70","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1021\/jm400938g","article-title":"Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives","volume":"56","year":"2013","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC71","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/molecules23061254","article-title":"Synthesis, design, and structure-activity relationship of the pyrimidone derivatives as novel selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"23","year":"2018","journal-title":"Molecules"},{"key":"2020103011412900000_BST-2020-0224CC72","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1039\/C1MD00118C","article-title":"N-substituted salicylamides as selective malaria parasite dihydroorotate dehydrogenase inhibitors","volume":"2","year":"2011","journal-title":"Med. Chem. Commun."},{"key":"2020103011412900000_BST-2020-0224CC73","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejmech.2018.11.044","article-title":"Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: synthesis, biological evaluation and X-ray structural studies","volume":"163","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC74","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1073\/pnas.0807398106","article-title":"Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase","volume":"106","year":"2009","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020103011412900000_BST-2020-0224CC75","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tibs.2009.08.004","article-title":"Plasmodium falciparum neutral aminopeptidases: new targets for anti-Malarials","volume":"35","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"2020103011412900000_BST-2020-0224CC76","doi-asserted-by":"publisher","first-page":"e0115859","DOI":"10.1371\/journal.pone.0115859","article-title":"Screening the medicines for malaria venture \u201cMalaria Box\u201d against the Plasmodium falciparum aminopeptidases, M1, M17 and M18","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"2020103011412900000_BST-2020-0224CC77","doi-asserted-by":"publisher","first-page":"e28589","DOI":"10.1371\/journal.pone.0028589","article-title":"The Plasmodium falciparum malaria M1 alanyl aminopeptidase (Pfa-M1): insights of catalytic mechanism and function from Md simulations","volume":"6","year":"2011","journal-title":"PLoS ONE"},{"key":"2020103011412900000_BST-2020-0224CC78","doi-asserted-by":"publisher","first-page":"43000","DOI":"10.1074\/jbc.M408123200","article-title":"A plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation","volume":"279","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC79","doi-asserted-by":"publisher","first-page":"E526","DOI":"10.1073\/pnas.1105601108","article-title":"Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases","volume":"108","year":"2011","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020103011412900000_BST-2020-0224CC80","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2174\/1381612023394197","article-title":"Cysteine proteases of malaria parasites: targets for chemotherapy","volume":"8","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"2020103011412900000_BST-2020-0224CC81","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.sbi.2013.07.015","article-title":"Working in concert: the metalloaminopeptidases from Plasmodium falciparum","volume":"23","year":"2013","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2020103011412900000_BST-2020-0224CC82","doi-asserted-by":"publisher","first-page":"27255","DOI":"10.1074\/jbc.M111.225318","article-title":"Distribution and biochemical properties of an M1-Family aminopeptidase in Plasmodium falciparum indicate a role in vacuolar hemoglobin catabolism","volume":"286","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2020103011412900000_BST-2020-0224CC83","doi-asserted-by":"publisher","first-page":"e31938","DOI":"10.1371\/journal.pone.0031938","article-title":"Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum","volume":"7","year":"2012","journal-title":"PLoS ONE"},{"key":"2020103011412900000_BST-2020-0224CC84","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1021\/jm070733v","article-title":"Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds","volume":"50","year":"2007","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC85","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1128\/AAC.06245-11","article-title":"The aminopeptidase inhibitor Chr-2863 is an orally bioavailable inhibitor of murine malaria","volume":"56","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"2020103011412900000_BST-2020-0224CC86","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1021\/jm101227t","article-title":"Synthesis of New (-)-Bestatin-based inhibitor libraries reveals a novel binding mode in the S1 pocket of the essential malaria M1 metalloaminopeptidase","volume":"54","year":"2011","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC87","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1016\/j.bmc.2017.06.047","article-title":"Kbe009: an antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library","volume":"25","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC88","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1021\/jm030795v","article-title":"The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity","volume":"46","year":"2003","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC89","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1021\/jm4005972","article-title":"Synthesis and structure-activity relationships of phosphonic arginine mimetics as inhibitors of the M1 and M17 aminopeptidases from Plasmodium falciparum","volume":"56","year":"2013","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bmc.2006.10.010","article-title":"A library of novel hydroxamic acids targeting the metallo-Protease family: design, parallel synthesis and screening","volume":"15","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC91","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1021\/jm061169b","article-title":"Novel selective inhibitors of the zinc plasmodial aminopeptidase Pfa-M1 as potential antimalarial agents","volume":"50","year":"2007","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC92","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1021\/jm900648x","article-title":"Hydroxamates: relationships between structure and plasma stability","volume":"52","year":"2009","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC93","doi-asserted-by":"publisher","first-page":"9168","DOI":"10.1021\/jm501323a","article-title":"Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors","volume":"57","year":"2014","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejmech.2016.01.015","article-title":"Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions","volume":"110","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC95","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/acs.jmedchem.8b01310","article-title":"Hydroxamic acid inhibitors provide cross-species inhibition of plasmodium M1 and M17 aminopeptidases","volume":"62","year":"2019","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC96","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/molecules23102607","article-title":"Aminobenzosuberone scaffold as a modular chemical tool for the inhibition of therapeutically relevant M1 aminopeptidases","volume":"23","year":"2018","journal-title":"Molecules"},{"key":"2020103011412900000_BST-2020-0224CC97","doi-asserted-by":"publisher","first-page":"103750","DOI":"10.1016\/j.bioorg.2020.103750","article-title":"Aminobenzosuberone derivatives as Pfa-M1 inhibitors: molecular recognition and antiplasmodial evaluation","volume":"98","year":"2020","journal-title":"Bioorg. Chem."},{"key":"2020103011412900000_BST-2020-0224CC98","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12936-017-2032-4","article-title":"Selective inhibition of Pfa-M1, over Pfa-M17, by an amino-Benzosuberone derivative blocks malaria parasites development in vitro and in vivo","volume":"16","year":"2017","journal-title":"Malar. J."},{"key":"2020103011412900000_BST-2020-0224CC99","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.molbiopara.2012.02.003","article-title":"Engagement of the S1, S1\u2032 and S2\u2032 subsites drives efficient catalysis of peptide bond hydrolysis by the M1-Family aminopeptidase from Plasmodium falciparum","volume":"183","year":"2012","journal-title":"Mol. Biochem. Parasitol."},{"key":"2020103011412900000_BST-2020-0224CC100","doi-asserted-by":"publisher","first-page":"10909","DOI":"10.1021\/jm301506h","article-title":"Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors","volume":"55","year":"2012","journal-title":"J. Med. Chem."},{"key":"2020103011412900000_BST-2020-0224CC101","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/cmdc.201800563","article-title":"Mapping the pathway and dynamics of bestatin inhibition of the Plasmodium falciparum M1 aminopeptidase PfA-M1","volume":"13","year":"2018","journal-title":"ChemMedChem."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/48\/5\/2067\/896478\/bst-2020-0224c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/48\/5\/2067\/896478\/bst-2020-0224c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T09:43:58Z","timestamp":1617097438000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/48\/5\/2067\/226276\/Driving-antimalarial-design-through-understanding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":101,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2020,10,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20200224","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}